Thiamidol containing treatment regimens in facial hyperpigmentation: An international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study

W. G. Philipp-Dormston*†, A. Vila Echague‡, S. H. Pérez Damonte§, J. Riedel**, A. Filbry**, K. Warnke**, C. Lofrano§, D. Roggenkamp** and G. Nippel**

*Hautzentrum Köln, Schillingsrötter Str. 39-41, Köln 50996, †Faculty of Health, University Witten/Herdecke, Witten 58455, Germany, ‡Centro de Referencia en Tratamiento Laser, Av. Del Libertador 662, Piso 17, depto. 42, Buenos Aires, §CLAIM, José Bonifacio 717, Buenos Aires, ¶BDF Argentina, Av Triunvirato 2902, Buenos Aires C1427 AAP CAB, Argentina and **Beiersdorf AG, Unnastrasse 48, Hamburg, 20245, Germany

Received 5 December 2019, Accepted 27 April 2020

Abstract

OBJECTIVE: Tyrosinase is the rate-limiting enzyme in melanogenesis. Thiamidol is the most potent inhibitor of human tyrosinase out of 50 000 tested compounds. In clinical studies, it was shown to improve facial hyperpigmentation, post-inflammatory hyperpigmentation and age spots significantly. To identify the optimal number of daily Thiamidol applications, we conducted a split-face study comparing the efficacy and tolerability of four-times with two-times daily application. Subsequently, we evaluated the efficacy and tolerability of a typical face care regimen containing Thiamidol in a real-world study.

METHODS: The split-face study was double-blind, randomized, controlled, including two Thiamidol containing products (serum and day care SPF 30). The serum was applied twice daily on one half of the face and the day care SPF30 twice-daily on the whole face. The real-world study was open-label, observational, including three Thiamidol containing products (day care SPF 30 in the morning, serum and night care in the evening). In both studies, subjects with mild-to-moderate facial hyperpigmentation applied the products over 12 weeks. Assessments included clinical and subjective grading of hyperpigmentation, skin condition, hemi-/modified MASI, chromameter and clinical photography.

RESULTS: In the split-face study (n = 34), hyperpigmentation, skin roughness and hMASI improved all significantly (P < 0.001) versus baseline, with first visible results after two weeks of twice-daily application. The four-times daily application led to significant improvement versus the two-times daily application. In the real-world study (n = 83), all evaluated parameters, including skin condition and chromametry (n = 30), improved significantly (P < 0.001) in comparison with baseline and the corresponding preceding visits. The subjects judged the cosmetic properties of the products positively. In both studies, the products were well tolerated.

CONCLUSION: Four-times daily Thiamidol improves facial hyperpigmentation significantly more than two-times daily and is well tolerated by the subjects. The real-world study with a typical face care regimen containing Thiamidol shows improvement of facial hyperpigmentation and confirms tolerability. Furthermore, the data provide evidence for the suitability of this three-product Thiamidol regimen for day-to-day life.

Résumé

OBJECTIF: La tyrosinase est l’enzyme qui limite le taux de mélanogénèse. Le Thiamidol est le plus puissant inhibiteur de la tyrosinase humaine parmi les 50 000 composés testés. Lors d’études cliniques, il a été démontré qu’il améliore de manière significative l’hyperpigmentation du visage, l’hyperpigmentation post-inflammatoire et les taches de vieillesse. Afin d’identifier le nombre optimal d’applications quotidiennes de Thiamidol, nous avons mené une étude hémigvisage comparant l’efficacité et la tolérance d’une application quatre fois par jour à une application deux fois par jour. Par la suite, nous avons évalué l’efficacité et la tolérance d’un régime de soins du visage typique contenant du Thiamidol dans le cadre d’une étude en situation réelle.

METHODES: L’étude hémigvisage était en double aveugle, randomisée et contrôlée, incluant deux produits contenant du Thiamidol (sérum et soin de jour SPF 30). Le sérum a été appliqué deux fois par jour sur une moitié du visage, et le soin de jour SPF30 deux fois par jour sur l’ensemble du visage. L’étude en situation réelle était ouverte, observationnelle, et comprenait trois produits contenant du Thiamidol (soin de jour SPF 30 le matin, sérum et soin de nuit le soir). Dans les deux études, les sujets présentaient une hyperpigmentation faciale légère à modérée ont appliqué les produits pendant 12 semaines. Les évaluations comprenaient une évaluation clinique et subjective de l’hyperpigmentation, de l’état de la peau, du hémigvisage, du chromamètre et de la photographie clinique.

RÉSULTATS: Dans l’étude hémigvisage (n = 34), l’hyperpigmentation, la rugosité de la peau et l’hMASI se sont tous améliorées de manière significative (P < 0.001) par rapport à la ligne de base, avec des effets devenus visibles après deux semaines d’application deux fois par jour. L’application quatre fois par jour a

© 2020 Beiersdorf AG, International Journal of Cosmetic Science published by John Wiley & Sons Ltd on behalf of Society of Cosmetic Scientists and Societe Francaise de Cosmetologie

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

[The copyright line for this article was changed on 06 October 2020 after original online publication]
apporté une amélioration significative par rapport à l’application deux fois par jour. Dans l’étude en situation réelle (n = 83), tous les paramètres évalués, y compris l’état de la peau et la chromométrie (n = 30) se sont améliorés significativement (P < 0.001) par rapport à la ligne de base et aux visites précédentes correspondantes. Les sujets ont jugé positivement les propriétés cosmétiques des produits. Dans les deux études, les produits ont été bien tolérés.

CONCLUSION: L’application de Thiamidol quatre fois par jour, améliore l’hyperpigmentation du visage de manière plus significative que deux fois par jour et est bien toléré par les sujets. L’étude en situation réelle avec un régime de soins du visage typique contenant du Thiamidol montre une amélioration de l’hyperpigmentation faciale et confirme la tolérance. En outre, les données fournissent des preuves de l’adéquation de ce régime de trois produits à base de Thiamidol pour le soin quotidien.

**Materials and methods**

**Split-face study**

**Study design**

This was a single-centre, double-blind, randomized, controlled, split-face clinical study conducted in a centre in the United States (Texas Research Center, Texas 75081).

After approval by the institutional review board, the study was conducted following the Declaration of Helsinki and the ICH GCP guidelines as applicable to cosmetic products. Before study inclusion, the subjects received the patient information and provided written, informed consent conforming to Title 21 Code of Federal Regulations (CFR) 50.25, including consent for photography.

**Study population and treatment**

Eligible for the study were healthy subjects (25–65 years, Fitzpatrick skin type I–IV) with mild-to-moderate hyperpigmentation (3–6 according to a modified Griffith’s 10-point scale, where 0 = none and 9 = severe [23]) on both sides of the face and willing to use the two test products. Pregnancy, allergies to skin care products, hormone replacement therapy or oral contraception within the previous 3 months, topical hyperpigmentation treatment within the previous 4 months, any topical or systemic medication known to affect skin ageing or dyschromia within the previous 8 weeks, any facial treatments, or photosensitizing or immunosuppressive drug application within the previous 6 months, high energy treatments, plastic surgery, or ablative laser resurfacing within the previous 12 months, extensive UV or other irradiation during the study, suntan, scars, birthmarks, skin cancer, chronic diseases (e.g., rosacea, psoriasis and acne) or strong hair growth on the face, poorly adjusted hypo- or hyperthyroïd persistence, health condition or pre-existing or dormant dermatologic disease on the face that could interfere with the outcome of the study, or concomitant participation to another clinical study were all exclusion criteria.

The subjects were allowed to follow their usual make-up and cleansing routine and applied the treatment regimen for 12 weeks as follows: Twice-daily serum on the assigned left or right side of the face and day care with SPF 30 on the whole face, that means, other two applications (Table 1); the subjects were not allowed to use any face care or make-up product in the mornings of the study visits. The INCI compositions of the study products are described in Table 2.

**Assessments**

Evaluations (Table 1) were conducted at visit 1 (baseline), visit 2 (week 2), visit 3 (week 4), visit 4 (week 8) and visit 5 (week 12) and included clinical photography [24], clinical grading of hyperpigmentation, skin roughness (baseline and week 12) and subjective assessment of hyperpigmentation (both with the modified Griffiths’ 10-point scale [23]), and MASI (including area [lesion size], darkness [pigment intensity] and homogeneity [19]) for half of the face [score 0–24, i.e. hemi-MASI] (weeks 4, 8 and 12). Full-face images were taken using a VISIA CR Photo station (Canfield Imaging Systems, Fairfield, New Jersey, USA) with a Canon Mark digital SLR camera (Canon Incorporated, Tokyo, Japan) under following lighting conditions: standard 1 and 2 and cross-polarized. The subjects acclimated at 20–23 °C and 35–65% relative humidity, at least 15 min prior to participating in any evaluation procedures.
Thiamidol improves facial hyperpigmentation
J. Philipp-Dormsten et al.

Study design
This was a single-arm, open-label, prospective, observational, real-world study conducted in one centre in Germany (HAUTZENTRUM Köln) and two centres in Argentina (CLAIM, Buenos Aires; Laser Therapy Clinic Dr. Agustina Vila Echague, Buenos Aires). In Germany, the study received approval by the local Ethics Committee and in Argentina by the corresponding Institutional Review Board. The study was conducted according to the Declaration of Helsinki and the ICH GCP guidelines as applicable to cosmetic products. All subjects received the patient information and provided written, informed consent, including photography.

Study population and treatment
Healthy subjects (25–60 years, Fitzpatrick skin type I–IV) with mild-to-moderate facial hyperpigmentation on both sides of the face and willing to use the three-product treatment regimen were included. Pregnancy, or hormone replacement therapy within the previous 3 months, topical hyperpigmentation treatment within the previous 2 months, any facial treatments, or photosensitizing drug application within the previous 6 months, extensive UV or other irritation during the study, sun-tan, scars, birthmarks, skin cancer, chronic diseases (e.g. rosacea, psoriasis and acne) or strong hair growth on the face, poorly adjusted hypo- or hyperthyreosis, known allergic reactions to any of the ingredients of the test regimen, or concomitant participation to another clinical study were all exclusion criteria.

The subjects were allowed to follow their usual make-up, cleansing, and sunscreen routine and applied the treatment regimen for 12 weeks as follows (Table 1):

- In the morning, day care cream with SPF 30;
- In the evening, serum and night care cream.

The subjects were not allowed to use any face care product in the mornings of the study visits. The INCI compositions of the study products are described in Table 2.

Table 2 INCI list

| Test product | INCI list |
|--------------|-----------|
| Serum (S)    | Aqua, Alcohol Denat, Butylene Glycol, Glycerin, Octocrylene, Isopropyl Palmitate, Cetearyl Isononanoate, Distarch Phosphate, Methylparanepanol, Isobutylamido Triazolyl Resorcinol, Sodium Ascorbyl Phosphate, Sodium Hyaluronate, Glycyrrhiza Inflata Root Extract, Tocopherol, Glucosyrlutin, Sodium Stearyl Glutamate, Glycerin, Stearate, Sodium Polyacrylate, Dimethicone, Isoqueritin, Citric Acid, Sodium Chloride, Trisodium Edta, Caprylyl Glycol, Phenoxyethanol, Parfum |
| Day care SPF30 (DC) | Methoxybenzoylbenzene, Ethylethyl Salicylate, Ethylethyl Triazone, Bis-Ethylehexyloxyphenol, Methoxypenyl Triazine, Butylene Glycol, Dicaprylate/Dicaprate, Tapioca Starch, Distarch Phosphate, C12-15 Alkil Benzaoate, Phenybenzimidazole Sulfonic Acid, Isobutylamido Triazolyl Resorcinol, Glycyrrhiza Inflata Root Extract, Tocopherol, Glucosyrlutin, Isoqueritin, Glycerin, Cetyl Alcohol, Stearyl Alcohol, Sodium Chloride, Xantham Gum, Carborner, Sodium Hydroxyde, Glycerin, Stearate, Sodium Stearyl Glutamate, Dimethicone, Phenoxyethanol, Trisodium Edta, Parfum |
| Night care cream (NC) | Aqua, Glycerin, Isopropyl Palmitate, Alcohol Denat, Cetearyl Isononanoate, Squalane, Panthenol, Glycerin, Stearate Citrate, Cetearyl Alcohol, Hydrogenated Coco-Glycerides, Butyropersomarum Parki Butter, Methylparanepanol, Lauryl Lysine, Isobutylamido Triazolyl Resorcinol, Glycyrrhiza Inflata Root Extract, Tocopherol, Glucosyrlutin, Carborner, Chondrus Crispus Extract, Sodium Hydroxyde, Isoqueritin, Trisodium Edta, Phenoxyethanol, Parfum |

Assessments
(Evaluations (Table 1) were conducted at visit 1 (baseline), visit 2 (week 4), visit 3 (week 8) and visit 4 (week 12). Subjective assessments included evenness, radiance, smoothness and hyperpigmentation all with the modified Griffiths’ 10-point scale [23]). The clinical assessments included skin condition (evenness, radiance and hyperpigmentation).
smoothness on a 5-point scale, 0 = extreme, e.g. extremely uneven skin tone, 4 = absent, e.g. very even skin tone) in both centres, nMASI (modified MASI without the homogeneity factor [19,25]) in Germany, and chromometer [26] (Chroma Meter CR-400® Konica Minolta, Japan) and clinical photography [24] in Argentina (Table 1). Full-face digital images (right and left side views) were taken using the Fotofinder Portrait® base/UVSCAN® [27] with a Canon C10 digital camera under standard lighting and the Dermoprime®. Before the instrumental evaluations, the subjects acclimatized for 15 min at a temperature of 20–23 °C and relative humidity of 35–65%. At the end of the study (visit 4), the subjects also answered (yes/no) a product performance questionnaire.

Statistics
We analysed the data descriptively (number, percentage, mean, standard deviation [SD], minimum and maximum) and used the Wilcoxon matched-pairs signed-ranks test to compare visits and

Figure 1 Selected digital images of two subjects before and after treatment with the combination (serum, day care SPF30) during the split-face study.
face sides. In the case of multiple comparisons, we used the Bonferroni-Holm correction of the level of significance. Differences were considered statistically significant at a $P < 0.005$ level.

**Results**

**Split-face study**

**Demographic characteristics**

Between April and August 2017, a total of 34 females aged 49.5 ± 8.5 years (range 25–64) were enrolled (Table 3).

**Clinical photography**

Clinical photography demonstrated a visible improvement of the hyperpigmentation from baseline to Week 12 after treatment with the combination of serum and day care SPF30 (Fig. 1).

**Clinical grading of skin condition**

After 12 weeks, application of the serum/day care SPF30 combination significantly improved both hyperpigmentation and skin roughness ($-0.78 ± 0.52, -0.87 ± 0.45$) versus baseline ($P < 0.001$) and versus the treatment with the day care SPF30 cream only ($-0.49 ± 0.40; -0.56 ± 0.32$) ($P < 0.001$; Fig. 2).

**Self-grading of skin condition**

The self-assessment also demonstrated at all-time points statistically significant improvement of the mean hyperpigmentation scores of...
the face sides treated with the combination versus baseline (week 2: $C_0 0.50$ and $C_6 0.60$; week 4: $C_0 0.99$ and $C_6 0.91$; week 8: $C_0 1.79$ and $C_6 1.67$; and week 12: $C_0 2.54$ and $C_6 1.70$) and versus the sides treated with the day care SPF30 only (week 2: $C_0 0.18$ and $C_6 0.39$; week 4: $C_0 0.25$ and $C_6 0.53$; week 8: $C_0 0.68$ and $C_6 1.15$; and week 12: $C_0 1.26$ and $C_6 1.26$; $P < 0.001$) (Fig. 3).

The combination treatment led to statistically significant hMASI reduction ($P < 0.001$) at all-time points versus baseline (week 4: $-0.72 \pm 1.05$ and week 8: $-1.76 \pm 1.69$; and week 12: $-2.43 \pm 1.96$) and versus the sides treated with the day care only (week 4: $-0.29 \pm 0.69$; week 8: $-0.84 \pm 1.45$; and week 12: $-1.26 \pm 1.52$; Fig. 4). The hMASI decreased from 6.12 at baseline to 3.69 at week 12 at the face sides treated with the combination and from 6.42 at baseline to 5.15 at week 12 at the sides treated with the day SPF30 cream only.

**Tolerability**

The analysis of the tolerability assessments showed no statistically significant changes from baseline for any parameter (erythema, oedema, dryness, burning, stinging or itching) at any time point for both sides of the face.

**Real-world study**

**Demographic characteristics**

Between August 2018 and April 2019, a total of 83 subjects (82 females) with a mean age of 44.7 ± 9.2 years (range 27–71) were enrolled. Demographics are summarized in Table 3.

**Clinical photography**

The improvement of hyperpigmentation after 12 weeks of treatment with the treatment regimen (day care SPF30, serum and night care) was documented by clinical photography (Figs 5 and 6).

![Figure 4](image1.png)

**Figure 4** Changes of hMASI scores (mean ± SD) from baseline to week 12. Scores were assessed after 4, 8 and 12 weeks of treatment. *Significant improvement ($P < 0.001$) compared with baseline and with treatment with day care SPF30 cream only. + Significant improvement compared with baseline ($P < 0.001$).

![Figure 5](image2.png)

**Figure 5** Representative Fotofinder Portrait® base/UVSCAN® images of a subject at baseline and after 12 weeks of treatment with the Thiamidol containing skin regimen (day care SPF30, serum and night care) during the real-world study.
Clinical grading of skin condition

In the course of the study, the means of all the skin condition parameters as assessed by the investigators significantly improved in comparison with baseline and with the previous visits ($P < 0.001$; Fig. 7). At week 12, mean evenness improved by 93.8% (from $1.6 \pm 0.9$ to $3.1 \pm 0.5$), radiance by 94.1% (from $1.7 \pm 0.7$ to $3.3 \pm 0.6$) and smoothness by 50.0% (from $2.2 \pm 1.0$ to $3.3 \pm 0.6$) versus baseline. From baseline to week

**Figure 6** Representative Dermoprime® images of a subject at baseline and after 12 weeks of treatment with the Thiamidol containing skin regimen (day care SPF30, serum and night care) during the real-world study.

**Figure 7** Clinical grading scores (0–4) at each time point for evenness, radiance and smoothness from all subjects (DE: Germany, AR: Argentina) considered for evaluation in the real-world study (mean values ± SD, $n = 83$, $*P < 0.001$ vs. baseline and versus preceding visit).
12, the evenness improved in 94% (n = 78) of the subjects and remained unchanged in 6.0% (n = 5), the radiance improved in 92.8% (n = 77) and remained unchanged in 7.2% (n = 6), and the smoothness improved in 78.3% (n = 65), remained unchanged in 18.1% (n = 15) and worsened in 3.6% (n = 3) of the subjects.

Self-grading of skin condition

Corresponding to the clinical grading were also the results from the subjects’ self-assessment (P < 0.001; Fig. 8). At week 12, mean evenness improved by 79.5% (from 3.9 ± 2.0 to 7 ± 1.6), radiance by 55.3% (from 4.7 ± 1.8 to 7.3 ± 1.9) and smoothness by 30.5% (from 5.9 ± 1.9 to 7.7 ± 1.7) versus baseline. Of the subjects, 89.2% (n = 74) found their evenness had improved, 9.6% (n = 8) that it was unchanged and 1.2% (n = 1) that it had worsened from baseline to week 12. The corresponding values for radiance were 86.7% (n = 72) improved, 6.0% (n = 5) unchanged and 7.2% (n = 6) worsened and for smoothness 77.1% (n = 64) improved, 15.7% (n = 13) unchanged and 7.2% (n = 6) worsened.

mMASI

The mMASI improved significantly from 8.5 ± 3.9 at baseline to 3.6 ± 2.6 at week 12 (P < 0.001). The improvement was statistically significant also when comparing visits 2-4 to the corresponding preceding visits (P ≤ 0.001; Fig. 9).

Chromameter

The mean luminosity value (L* parameter) increased significantly (P < 0.001) from 58.4 ± 3.5 at baseline to 59.6 ± 3.2 at week 4, to 60.5 ± 2.9 at week 8 and to 60.7 ± 2.8 at week 12, corresponding to an average change of 4.02%. The differences were significant between all possible pairs of L* means (P < 0.001) (Fig. 10).

Figure 8

Self-assessment by modified Griffiths’ score (1–10) at each time point for evenness, radiance and smoothness from all subjects considered for evaluation in the real-world study (mean ± SD, n = 83, *P < 0.001 vs. baseline and versus preceding visit).

Figure 9

Changes of mMASI scores (mean ± SD) from baseline to week 4 (−1.3 ± 2.0), week 8 (−2.8 ± 2.9) and week 12 (−4.9 ± 3.0) (n = 32) in the real-world study. Significances are indicated in comparison with baseline (**P ≤ 0.01, ***P ≤ 0.001).
Subjective assessment of product performance

Over 90% of the subjects rated all subjective performance questions positively, answering the respective questions with ‘yes’. The corresponding results are listed in Table 4.

Tolerability

The investigators rated the tolerability of the product as very good in 73.5% \((n = 61)\), as good in 22.9% \((n = 19)\) and as satisfactory in 3.6% \((n = 3)\) of the subjects.

Discussion

The split-face study demonstrated in the clinical setting and already after two weeks that four-times daily Thiamidol was visibly and significantly more effective than twice-daily in all assessments and corresponding time points. The release of the active from the two products (serum and day care) is expected to be comparable. Therefore, the results from the split-face study are indicating the benefit of a higher application frequency over a lower. The significant improvement continued until the end of the study in both sides of the face. The second study showed the efficacy, day-to-day acceptability and excellent tolerability, of a typical face care regimen containing the human tyrosinase inhibitor in a real-world setting. These results underline the real-life suitability of the products and their compatibility with the usual make-up and cleansing routines.

The reduction of the MASI Score was in both studies significant, considerable, and in-line with earlier made observations [20]. The value of hMASI in the split-face study was smaller because, per definition, it represents the area of half the face. Duplication of the hMASI corresponds to mMASI in the real-world study. We chose the modified MASI because it was shown to be a reliable, valid and responsive to change method for the assessment of melasma severity. Besides, mMASI was demonstrated to be more convenient to use than MASI [25].

In addition to hyperpigmentation also skin roughness, evenness, radiance and smoothness improved significantly. Investigators and subjects confirmed the visible improvements, which were also documented by clinical photography and chromametry. The two latter standardized methods are objective, excluding interobserver variability and difficulty of remembering the baseline condition at the subsequent visit [24]. However, subjective assessments of efficacy are also essential to estimate compliance, especially for conditions such as hyperpigmentation, the treatment of which is challenging and frustrating for patients and physicians [5,10].

In the real-world study, the overall skin improvements and tolerability of the three-product regimen led to good overall acceptance. Over 90% of the subjects agreed that the products have a pleasant texture and are skin-compatible. Results, which are supporting adherence to the treatment. Therefore, we conclude the suitability of this three-product regimen for day-to-day life.

The studies were conducted on both sides of the hemisphere, covered most seasons except summer and various sun intensities to reflect real-world conditions. Based on an earlier study [20], in which half of the patients applied the treatment during the low ambient-UV time of the year and the other half during the high ambient-UV period, we expected no seasonal effects. Nevertheless, as UV-radiation can promote or worsen hyperpigmentation [28,29], sunscreen use is mandatory [30,31]. Therefore, SPF 30 was added in the day care product, which was used by all subjects, excluding thus possible confounding by sun exposure.

Table 4 Self-grading of product performance

| Questions on product performance                                      | Patients answering ‘yes’ (%) |
|-----------------------------------------------------------------------|-----------------------------|
| The serum has a pleasant texture                                      | 97.6                        |
| The serum is skin-compatible                                          | 97.6                        |
| The day care has a pleasant texture                                   | 97.5                        |
| The day care is skin-compatible                                       | 91.4                        |
| The night care has a pleasant texture                                 | 92.8                        |
| The night care is skin-compatible                                     | 92.6                        |
| The products are suitable for my skin                                 | 93.8                        |
| My skin feels cared for                                               | 93.8                        |
| My dark spots appear less pronounced                                  | 97.6                        |
| The products improve the appearance of dark spots                     | 95.2                        |
| The products even out my skin                                         | 91.6                        |
| My skin tone looks more even                                          | 93.8                        |
| The products provide a smooth skin                                   | 90.0                        |
| The products provide a radiant complexion                             | 93.7                        |

Figure 10 Change of chromameter luminosity \((L^*\) value, mean ± SD) versus baseline in the real-world study \((n = 30, *P < 0.001)\).
subjects were not allowed to use other face care products for the duration of the studies, we can assume that no other substances influenced the results. Furthermore, a safety assessment including photosensitivity tests demonstrated that Thiamidol does not induce UV sensitivity (data on file).

As hyperpigmentation may have intrinsic or extrinsic triggers [32] affecting all ages, we included adult subjects of 25–65 years in the two studies. The studies’ populations were too small for age-specific sub-group analyses, something to consider for the future. However, the lightening effect of Thiamidol on age spots was shown earlier [17]. Similarly, previous studies (and yet unpublished results) showed that the molecule is efficacious in all ethnicities [20]. Thus, in the two studies reported here, we did not focus on ethnic groups. Nevertheless, as hyperpigmentation has a higher prevalence in darker skin types [33], a future study could focus on those. Furthermore, because of the higher prevalence, we focused here on women. Only one man was included in the real-world study, not allowing sex-specific conclusions.

The results reported here supplement and confirm the so far with Thiamidol conducted investigations. Unfortunately, it was not possible to determine all parameters in every centre, affecting the comparability of the results. However, the overall design, duration, visit frequency and methods chosen here are typical for this kind of studies [34–36].

In conclusion, Thiamidol four-times daily is well tolerated and provides significant visible improvement of hyperpigmentation versus baseline and twice-daily application. The regimen approach with the three products (serum, day care SPF30 and night care) is also well tolerated, effective and suitable for the day-to-day life of people suffering from facial hyperpigmentation.

Acknowledgements

The studies were sponsored by Beiersdorf AG. The test products were provided by Beiersdorf AG (Hamburg, Germany). KW, AF, JR, CL, DR and GN are employees of Beiersdorf AG. AVE, SPD and WPD conducted the studies. Medical writing support was provided by Helena Karajiannis (HK Scientific Consulting, Basel, Switzerland) and was funded by Beiersdorf AG.

References

1. Kang, W.H., Yoon, K.H., Lee, E.S. et al. Melasma: histopathological characteristics in 56 Korean patients. Br. J. Dermatol. 164, 228–237 (2006).
2. Guinot, C., Cheffai, S., Latreille, J. et al. Aggravating factors for melasma: a prospective study in 197 Tunisian patients. J. Eur. Acad. Dermatol. Venereol. 24, 1060–1069 (2010).
3. Nomakhosi, M. and Heidi, A. Natural options for management of melasma, a review. J. Cosmet. Laser Ther. 20, 470–481 (2018).
4. McKesey, J., Tovar-Garza, A. and Pandya, A.G. Melasma treatment: an evidence-based review. Am. J. Clin. Dermatol. 21, 173–225 (2020).
5. Maymone, M.B.C., Neamah, H.H., Wirya, S.A. et al. The impact of skin hyperpigmentation and hyperchromia on quality of life: A cross-sectional study. J. Am. Acad. Dermatol. 77, 775–778 (2017).
6. Chang, T.S. An updated review of tyrosinase inhibitors. Int. J. Mol. Sci. 10, 2440–2475 (2009).
7. Gilbro, J.M. and Olsson, M.J. The melanogenesis and mechanisms of skin-lightening agents—existing and new approaches. Int. J. Cosmetic. Sci. 33, 210–221 (2011).
8. Pillaiyar, T., Namastivayam, V., Manickam, M. and Jung, S.H. Inhibitors of melanogenesis: an updated review. J. Med. Chem. 61, 7995–7918 (2018).
9. Zaidi, K.U., Ali, S.A., Ali, A. and Naan, I. Natural tyrosinase inhibitors: role of herbs in the treatment of hyperpigmentary disorders. Mini Rev. Med. Chem. 19, 796–808 (2019).
10. Kumari, S., Tiern Gaazan Thng, S., Kumar Verma, N. and Gausam, H. Melanogenesis inhibitors. Acta Derm. Venereol. 98, 924–931 (2018).
11. Mann, T., Gerwat, W., Roehm, K. and Kolbe, L. Isobutylamido thiazolyl resorcinol a highly effective inhibitor of human tyrosinase. In: 27th EADV Congress 2018, EADV, Paris, France (2018).
12. Council Regulation (EC) 1223/2009 on cosmetic products, OJ. L342 (2009).
13. Gunia-Krzyzak, A., Poptol, J. and Marona, H. Melanogenesis inhibitors: strategies for searching for and evaluation of active compounds. Curr. Med. Chem. 23, 3548–3574 (2016).
14. Espin, J.C., Varon, R., Fennol, L.G. et al. Kinetic characterization of the substrate specificity and mechanism of mushroom tyrosinase. Eur. J. Biochem. 267, 1270–1279 (2000).
15. García-Molina, F., Hiner, A.N., Fennol, L.G. et al. Mushroom tyrosinase: catalase activity, inhibition, and suicide inactivation. J. Agric. Food Chem. 53, 3702–3709 (2005).
16. Cordes, P., Sun, W., Wolber, R., Kolbe, L., Klebe, G. and Rohm, K.H. Expression in non-melanogenic systems and purification of soluble variants of human tyrosinase. Biol. Chem. 394, 685–693 (2013).
17. Mann, T., Gerwat, W., Bataer, J. et al. Inhibition of human tyrosinase requires molecular motifs distinctively different from mushroom tyrosinase. J. Invest. Dermatol. 138, 1601–1608 (2018a).
18. Mann, T., Scherner, C., Rohm, K.H. and Kolbe, L. Structure-activity relationships of thiazolyl resorcinols, potent and selective inhibitors of human tyrosinase. Int. J. Mol. Sci. 19, 690 (2018b).
19. Pandya, A.G., Hynan, L.S., Ihorer, B. et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J. Am. Acad. Dermatol. 64, 78–83.e2 (2011).
20. Arrowitz, C., Schoellermann, A.M., Mann, T., Jiang, L.L., Weber, T. and Kolbe, L. Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to moderate melasma. J. Invest. Dermatol. 139, 1691–1698 e6 (2019).
21. Roggenkamp, D., Neulang, G., Pillay, A., Zoric, I., Kaush, M. and Ilova, N.C. A skin care regimen with Thiamidol effectively reduces post-inflammatory hyperpigmentation in patients with resolved acne. In: 28th EADV Congress 2019, Madrid (2019).
22. Statista GmbH, S. Dekorative Kosmetik und Gesichtspflege 2019. In: Kosmetik & Körperpflege. (Statista ed.), (2019), https://de.statista.com/statistik/studie/64562/dokument/dekorative-kosmetik-und-gesichtspfllege/, last visited April 2020.
23. Griffiths, C.E., Wang, T.S., Hamilton, T.A., Voorhees, J.J. and Ellis, C.N. A photometric scale for the assessment of cutaneous photodamage. Arch. Dermatol. 128, 347–351 (1992).
24. Taylor, S., Westerhof, W., Im, S. and Lim, J. Noninvasive techniques for the evaluation
of skin color. *J. Am. Acad. Dermatol.* **54**(5 Suppl 2), S282–S290 (2006).

25. Abou-Taleb, D.A., Ibrahim, A.K., Youssef, E.M. and Moubasher, A.E. Reliability, validity, and sensitivity to change overtime of the modified melasma area and severity index score. *Dermatol. Surg.* **43**, 210–217 (2017).

26. Clarys, P., Alewaeters, K., Lambrecht, R. and Barel, A.O. Skin color measurements: comparison between three instruments: the Chromameter(R), the DermaSpectrometer(R) and the Mexameter(R). *Skin Res. Technol.* **6**, 230–238 (2000).

27. FotoFinder(R). In. *FotoFinder Systems*, ed., https://www.fotofinder-systems.com/technology/aesthetics/aesthetics-face/, last visited April 2020.

28. Lee, B.W., Schwartz, R.A. and Janniger, C.K. Melasma. *G. Ital. Dermatol. Venereol.* **152**, 36–45 (2017).

29. Masaki, H. Role of antioxidants in the skin: anti-aging effects. *J. Dermatol. Sci.* **58**, 85–90 (2010).

30. Becker, S., Schiekofer, C., Vogt, T. and Reichrath, J. Melasma: An update on the clinical picture, treatment, and prevention. *Hautarzt.* **68**, 120–126 (2017).

31. Schalka, S. New data on hyperpigmentation disorders. *J. Eur. Acad. Dermatol. Venereol.* **31**(Suppl 5), 18–21 (2017).

32. Rigopoulos, D., Gregoriou, S. and Katsambas, A. Hyperpigmentation and melasma. *J. Cosmet. Dermatol.* **6**, 195–202 (2007).

33. Ogbechie-Godec, O.A. and Elbuluk, N. Melasma: an up-to-date comprehensive review. *Dermatol. Ther. (Heidelberg).* **7**, 305–318 (2017).

34. Serra, M., Bohnert, K., Narda, M., Granger, C. and Sadick, N. Brightening and improvement of facial skin quality in healthy female subjects with moderate hyperpigmentation or dark spots and moderate facial aging. *J. Drugs Dermatol.* **17**, 1310–1315 (2018).

35. Bruce, S. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months. *J. Drugs Dermatol.* **12**, S27–31 (2013).

36. Lim, J.T. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. *Dermatol. Surg.* **25**, 282–284 (1999).